NCT02532283View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

December 11, 2015

Primary Completion Date

February 24, 2017

Study Completion Date

March 15, 2017

Conditions
Influenza A Virus
Interventions
DRUG

JNJ-63623872

Participants will be administered JNJ-63623872 600 milligram (mg) tablets orally twice daily for 7 days.

DRUG

Placebo

Participants will be administered placebo tablets orally twice daily for 7 days.

DRUG

Oseltamivir

Participants will be administered oseltamivir 75 mg capsules orally twice daily for 7 days.

Trial Locations (68)

Unknown

Fresno

Long Beach

Stanford

Atlantis

Miami

Chicago

Detroit

Royal Oak

Troy

Minneapolis

St Louis

Teaneck

Winston-Salem

Houston

Cairns

South Brisbane

Westmead

Aalst

Brussels

Leuven

Passo Fundo

Porto Alegre

São Paulo

Hamilton

Québec

Dijon

Grenoble

Limoges

Lyon

Nantes

Paris

Poitiers

Rennes

Saint-Priest-en-Jarez

Tours

Donaustauf

Jena

Hong Kong

Kota Bharu

Kuala

Kuala Lumpur

Kuching

Malacca

Miri

Sungai Buloh

Taiping

Rotterdam

Utrecht

Zutphen

Hamilton

Singapore

Alicante

Barcelona

Bizkaia

Elche

Granada

Madrid

Mataró

San Sebastián

Vigo

Malmo

Umeå

Uppsala

Ankara

Eskişehir

Istanbul

Izmir

Trabzon

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02532283 - A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection | Biotech Hunter | Biotech Hunter